# SURTIME (NCT01099423)

> Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01099423
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Conditions: Kidney Cancer
- Interventions: timing of surgery; gene expression analysis; biologic sample preservation procedure; laboratory biomarker analysis; therapeutic conventional surgery
- Enrollment: 99
- Primary outcome: Overall progression-free survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 10
- Podcasts: 4
- YouTube: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=surtime-nct01099423

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01099423", "email": "<work email>"}; the inbox owner confirms by the emailed link.